Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
|Articles|March 1, 2002
- Pharmaceutical Technology-03-02-2002
- Volume 26
- Issue 3
Drug Safety Concerns Shape Manufacturing Policy
Author(s)Jill Wechsler
FDA wants manufacturers to revise product labeling and packaging and step up adverse-event monitoring to reduce risky product use.
Advertisement
Articles in this issue
over 24 years ago
Outsourcing Outlookover 24 years ago
Developing Custom Adhesive Systems for Transdermal Drug Deliveryover 24 years ago
PDA Task Force Issues Guidelines to Aid Isolator Usersover 24 years ago
Production Information Mangementover 24 years ago
Validation Changes to the USP Assay Method for Ibuprofen Tabletsover 24 years ago
Systematic Troubleshooting for LC/MS/MSAdvertisement
Related to this article
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5